Article
Clinical Neurology
Aenne S. von Falkenhausen, Katharina Feil, Moritz F. Sinner, Sonja Schoenecker, Johanna Mueller, Johannes Wischmann, Elodie Eiffener, Sebastian Clauss, Sven Poli, Khouloud Poli, Christine S. Zuern, Ulf Ziemann, Jorg Berrouschot, Alkisti Kitsiou, Wolf-Rudiger Schaebitz, Marianne Dieterich, Steffen Massberg, Stefan Kaeaeb, Lars Kellert
Summary: This study introduces a novel non-invasive method for assessing the risk of atrial fibrillation (AF) after embolic strokes of undetermined source (ESUS) using digital electrocardiogram recordings. The results indicate that rhythm irregularity burden is the strongest predictor of AF. This research helps determine the risk of AF in ESUS patients and guide AF detection.
ANNALS OF NEUROLOGY
(2023)
Article
Medicine, General & Internal
Gregory F. Michaud, William G. Stevenson
Summary: A 63-year-old healthy male with atrial fibrillation presents with symptoms of dyspnea and irregular heartbeat. Physical examination reveals high blood pressure, irregular pulse, and ECG confirms atrial fibrillation. Further evaluation and treatment plan are needed.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Sharon Louise Cadogan, Emma Powell, Kevin Wing, Angel Yun Wong, Liam Smeeth, Charlotte Warren-Gash
Summary: Among patients with newly diagnosed atrial fibrillation, treatment with direct oral anticoagulants (DOACs) was associated with a reduced incidence of dementia and mild cognitive impairment, with a 16% reduction in dementia diagnosis and a 26% reduction in incident MCI compared to treatment with Vitamin K antagonists (VKAs).
Article
Medicine, General & Internal
Gregory Y. H. Lip, Allison Keshishian, Yan Zhang, Amiee Kang, Amol D. Dhamane, Xuemei Luo, Christian Klem, Mauricio Ferri, Jenny Jiang, Huseyin Yuce, Steven Deitelzweig
Summary: In this study of patients with NVAF and high risk of GI bleed, NOACs were associated with lower rates of stroke and/or SE, but NOACs had varying risks of MB compared with warfarin. These results may help inform treatment options in this patient population.
Article
Multidisciplinary Sciences
Steffen Blum, Stefanie Aeschbacher, Michael Coslovsky, Pascal B. Meyre, Philipp Reddiess, Peter Ammann, Paul Erne, Giorgio Moschovitis, Marcello Di Valentino, Dipen Shah, Juerg Schlaepfer, Rahel Mueller, Juerg H. Beer, Richard Kobza, Leo H. Bonati, Elisavet Moutzouri, Nicolas Rodondi, Christine Meyer-Zuern, Michael Kuehne, Christian Sticherling, Stefan Osswald, David Conen
Summary: This study aimed to investigate the association between types of atrial fibrillation (AF) and adverse outcomes. Through the follow-up of 3843 AF patients, it was found that the type of AF was not associated with the incidence of stroke or systemic embolism.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Mette Sogaard, Flemming Skjoth, Peter B. Nielsen, Jesper Smit, Michael Dalager-Pedersen, Torben B. Larsen, Gregory Y. H. Lip
Summary: This population-based cohort study found that new-onset atrial fibrillation after community-acquired pneumonia is associated with an increased risk of thromboembolism, which suggests the need for anticoagulation therapy. Approximately one-third of patients had a new hospital or outpatient clinic contact for atrial fibrillation within 3 years, indicating that atrial fibrillation triggered by acute infections is not a transient condition.
Article
Cardiac & Cardiovascular Systems
Rita Carolina Figueiredo Duarte, Danyelle Romana Alves Rios, Estevao Lanna Figueiredo, Jose Raymundo Sollero Caiaffa, Francisco Resende Silveira, Rodrigo Lanna, Luan Carlos Vieira Alves, Gabriela Lopes Martins, Helton Jose Reis, Edna Afonso Reis, Claudia Natalia Ferreira, Eduardo Back Sternick, Fernanda Magalhaes Freire Campos, Maria das Gracas Carvalho
Summary: This study evaluated the hemostasis in patients with non-valvular atrial fibrillation undergoing warfarin or rivaroxaban treatment, showing that warfarin users had lower levels of coagulation while rivaroxaban users exhibited higher levels. Additionally, the use of oral anticoagulants significantly reduced levels of monocyte-platelet aggregates, glycoprotein IIb/IIIa, and platelet and endothelium microparticles.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2021)
Article
Clinical Neurology
Alvi A. Rahman, Jonathan Michaud, Sophie Dell'Aniello, Erica E. M. Moodie, James M. Brophy, Madeleine Durand, Jason R. Guertin, Jean-Francois Boivin, Christel Renoux
Summary: In patients with nonvalvular atrial fibrillation (NVAF), the use of oral anticoagulants (OACs) is associated with a decreased risk of dementia, particularly in elderly individuals.
Article
Medicine, General & Internal
S. J. Connolly, G. Karthikeyan, M. Ntsekhe, A. Haileamlak, A. El Sayed, A. El Ghamrawy, A. Damasceno, A. Avezum, A. M. L. Dans, B. Gitura, D. Hu, E. R. Kamanzi, F. Maklady, G. Fana, J. A. Gonzalez-Hermosillo, J. Musuku, K. Kazmi, L. Zuhlke, L. Gondwe, C. Ma, M. Paniagua, O. S. Ogah, O. J. Molefe-Baikai, P. Lwabi, P. Chillo, S. K. Sharma, T. T. J. Cabral, W. M. Tarhuni, A. Benz, M. van Eikels, A. Krol, D. Pattath, K. Balasubramanian, S. Rangarajan, C. Ramasundarahettige, B. Mayosi, S. Yusuf
Summary: Among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy leads to a lower rate of a composite of cardiovascular events or death compared to rivaroxaban therapy, without a higher rate of bleeding.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Nicolas M. Van Mieghem, Martin Unverdorben, Christian Hengstenberg, Helge Moellmann, Roxana Mehran, Diego Lopez-Otero, Luis Nombela-Franco, Raul Moreno, Peter Nordbeck, Holger Thiele, Irene Lang, Jose L. Zamorano, Fayaz Shawl, Masanori Yamamoto, Yusuke Watanabe, Kentaro Hayashida, Rainer Hambrecht, Felix Meincke, Pascal Vranckx, James Jin, Eric Boersma, Josep Rodes-Cabau, Patrick Ohlmann, Piera Capranzano, Hyo-Soo Kim, Thomas Pilgrim, Richard Anderson, Usman Baber, Anil Duggal, Petra Laeis, Hans Lanz, Cathy Chen, Marco Valgimigli, Roland Veltkamp, Shigeru Saito, George D. Dangas
Summary: In patients with atrial fibrillation after successful transcatheter aortic-valve replacement, edoxaban was noninferior to vitamin K antagonists in terms of a composite outcome, but had a higher incidence of major bleeding.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Clinical Neurology
So-Ryoung Lee, Eue-Keun Choi, Sang-Hyun Park, Jin-Hyung Jung, Kyung-Do Han, Seil Oh, Gregory Y. H. Lip
Summary: The study found that among patients with atrial fibrillation, there was no significant difference in the risk of dementia between those treated with DOACs and warfarin. However, DOACs may be more beneficial than warfarin in younger patients or those with a history of stroke. Among the different DOACs, only edoxaban was associated with a lower risk of dementia compared to warfarin.
Article
Endocrinology & Metabolism
Jia-Yi Huang, Yi-Kei Tse, Hang-Long Li, Cong Chen, Chun-Ting Zhao, Ming-Ya Liu, Mei-Zhen Wu, Qing-Wen Ren, Si-Yeung Yu, Denise Hung, Xin-Li Li, Hung-Fat Tse, Gregory Y. H. Lip, Kai-Hang Yiu
Summary: This study evaluated the association between prediabetes and heart failure, as well as the association of heart failure with changes in glycemic status. The results showed that prediabetes was associated with an increased risk of heart failure, while reverting to normoglycemia was associated with a decreased risk of heart failure.
Article
Cardiac & Cardiovascular Systems
Sergio Raposeiras-Roubin, Emad Abu-Assi, Tamara Fernandez Sanz, Cristina Barreiro Pardal, Isabel Munoz Pousa, Maria Melendo Viu, Pablo Dominguez Erquicia, Ana Ledo Pineiro, Andrea Lizancos Castro, Inmaculada Gonzalez Bermudez, Xavier Rossello, Borja Ibanez, Andres Iniguez Romo
Summary: This study aimed to assess the impact of cancer on the prediction and risk of embolic and hemorrhagic events in patients with atrial fibrillation (AF). It found that while cancer was associated with an increased risk of bleeding, it was not associated with an increased risk of embolic events. Active cancer decreased the accuracy of the scores used to predict bleeding and embolic risk in nonanticoagulated patients.
REVISTA ESPANOLA DE CARDIOLOGIA
(2023)
Article
Endocrinology & Metabolism
David Tak Wai Lui, Eric Ho Man Tang, Ivan Chi Ho Au, Tingting Wu, Chi Ho Lee, Chun Ka Wong, Chloe Yu Yan Cheung, Carol Ho Yi Fong, Wing Sun Chow, Yu Cho Woo, Kathryn Choon Beng Tan, Karen Siu Ling Lam, Carlos King Ho Wong
Summary: This retrospective cohort study compared the effect of warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) on fracture risk in patients with type 2 diabetes and atrial fibrillation (AF) using a population-based electronic database. The results showed that NOAC use was associated with a lower risk of major osteoporotic fractures compared to warfarin use.
Article
Hematology
Christos Voukalis, Gregory Y. H. Lip, Eduard Shantsila
Summary: Patients with atrial fibrillation have more potent thrombogenesis and delayed clot dissolution compared to disease control groups. Apixaban is more effective in attenuating prothrombotic characteristics and reducing biomarkers associated with adverse cardiovascular events compared to warfarin and antiplatelets.
THROMBOSIS RESEARCH
(2021)